MAPK3 and non-small cell lung carcinoma: In non small cell lung cancer, the H-RAS/MEK/ERK1/2 pathway not only up-regulates PD-1L but also down-regulates the NK group 2 member D (NKG2D), a key ligand activating NK cells [164].